UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM 8-K |
| |
| CURRENT REPORT |
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| |
| Date of Report (Date of earliest event reported):June 22, 2020 |
| AIKIDO PHARMA INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | | 000-05576 | | 52-0849320 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| One Rockefeller Plaza, 11th Floor, New York, NY | | 10020 |
| (Address of principal executive offices) | | (Zip Code) |
| |
| Registrant’s telephone number, including area code: (703) 992-9325 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Stock, $0.0001 par value | | AIKI | | The Nasdaq Capital Market |
On June 22, 2020, certain owners (the “Sellers”) of 1,512,465 shares of common stock, par value $0.001 (the “Shares”), of AIkido Pharma Inc., a Delaware corporation (the “Company”), sold the Shares to a healthcare-dedicated investment fund (the “Fund”), pursuant to that certain Stock Purchase Agreement, by and among the Fund and the Sellers (the “Sale”). The Shares sold in the Sale were subject to restrictions (the “Restrictions”) pursuant to that certain Leak-Out Agreement, dated as of December 5, 2019, by and between the Company and CBM BioPharma, Inc., a Delaware corporation. The Restrictions were lifted pursuant to that certain Termination Agreement, dated as of June 24, 2020, by and between the Company and the Fund.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AIKIDO PHARMA INC. |
| | |
| | By: | /s/ Anthony Hayes |
| | Name: Title: | Anthony Hayes
Chief Executive Officer |
Dated: June 25, 2020
